Helping to Bring Improved and Novel Therapies to the Right Patient Population Faster
Compound profiling on EGFR mutants and osimertinib-resistant cell lines
Mutations in the epidermal growth factor receptor (EGFR) are the most common oncogenic drivers in non-small cell lung [...]
Cancer cell panel profiling of MAPK pathway inhibitors
The MAPK signal transduction pathway plays a key role in tumor progression. Mutations in the corresponding driver genes, [...]
Compound profiling in PARP inhibitor-resistant cancer cell lines
Drug resistance is a major problem in the treatment of cancer. Many aspects of clinical drug resistance can [...]